Jazz Pharmaceuticals: Options Enthusiasm Meets a Growing Short Book

Jazz Pharmaceuticals reports Q3 results today with a striking split between how options traders and short sellers are positioned going into the print.

Options positioning has turned decisively bullish, more so than at almost any point in the past year. The put/call ratio dropped to 0.19, well below the 20-day average of 0.41 and sitting near the 52-week low of 0.13. That reading is about 1.2 standard deviations below the recent mean, reflecting heavy demand for upside exposure rather than downside protection. The stock itself closed at $215.98, up 3.9% on Friday but down 7% over the past month, leaving it trailing the median one-week gain of around 5.4% among its closest peers. The borrow market tells a calm story: availability is ample at nearly 700% of shares already borrowed, meaning for every share lent out there are roughly seven more available to borrow, with cost to borrow a low 0.43%.

The short interest picture is more ambivalent. At 9.2% of the free float, the short book is meaningful and has grown about 11% over the past month, even as it edged down 3.4% over the past week. That month-long build happened while the share price was falling, suggesting some bears have been positioning against a disappointing print rather than simply covering into weakness. JP Morgan raised its target to $300 from $276 the day before results, keeping an Overweight rating, while Morgan Stanley trimmed its target modestly to $314. Both remain positive, and Goldman Sachs reinstated coverage in September with a Buy and a $337 target. The analyst consensus price implies roughly 37% upside from the current price, a wide gap that reflects both conviction and the stock's recent slide from higher levels.

The bull case rests on portfolio diversification well beyond the company's legacy Xyrem franchise. Ziihera's broadened approval in first-line HER2-positive gastroesophageal cancer raised management's peak revenue view to $3 billion to $5 billion, and the neuroscience franchise through Xywav and Epidiolex continues to grow. Bears point to pipeline risk around Zepzelca in first-line small cell lung cancer, slower-than-expected growth in Rylaze and Epidiolex, and the threat of generic pressure on older products including a potential generic entry into Epidiolex from 2027.

One external data point adds texture without forecasting the print. Medicaid dollars reimbursed for Jazz's drugs, as tracked by the Centers for Medicare and Medicaid Services, have risen for four consecutive quarters and were up 11% year over year in the first quarter of 2026, reaching $219 million. That streak reflects durable reimbursement uptake across the portfolio. There are no datasets with a measured lead to the company's reported figures, so this reading describes commercial momentum in the Medicaid channel, not what the quarter's numbers will show.

The earnings report will test whether the neuroscience and oncology portfolio can produce revenue that closes the gap between the stock's current price and an analyst consensus that has moved consistently higher even as the shares have not.